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Gene regulation networks are the representation of multiple levels
within a cell1. They provide a global view intended to help understand
how relationships between molecules dictate cellular behavior. The
recent advances in molecular biology and cutting-edge technologies
reveal the emerging role of microRNAs in major physiological and
pathological processes. microRNAs are small non-coding RNAs
involving in post-transcriptional regulation of gene expression by
binding to the 30-UTRs of the target mRNAs. Many microRNA
targets are key regulators of lipid metabolism and disease in the liver,
suggesting the functional involvement of microRNAs in this process.
In this review, we provide new insight into the speciﬁc role of
microRNAs in lipid metabolism.2. microRNA regulation network
microRNA genes are normally transcribed by Polymerase II or III2 to
generate primary-miRNAs (pri-miRNAs). These large RNA transcripts
often contain several hundreds of base pairs in length and encode
sequences for multiple miRNA genes. Before exported out of the
nucleus by expertin-5, pri-miRNAs, which are capped and polyade-
nylated, need to be cleaved by Drosha to form hairpin-shaped stem-
loop structures of approximately 60–70 nucleotides (nt), namely
precursor-miRNAs (pre-miRNAs). In the cytoplasm, the pre-
miRNAs are further processed by a second RNase III enzyme, named
Dicer, into a miRNA-miRNAn duplex. One strand of the duplex,
serving as the “guide” strand, is loaded into miRNP, a large multi-
protein miRNA ribonucleoprotein complex, and is used to modulate
target gene expression. The other strand of the duplex, namely
miRNAn, is excluded and degraded1. When the two strands of the
pre-miRNA are more equal in their distribution, the opposite stand is
named miRNA-3p instead of miRNAn. In turn, the guide stand is
referred to as miRNA-5p, depending on the location to either 50 or 30
of the target miRNA molecule. Both strands could potentially have
biological effects3.
In addition to the canonical miRNA biogenesis pathway, alternative
pathways are emerging, including Drosha/DGCR8-independent or
Dicer-independent pathway4. In the Drosha/DGCR8-independent path-
way, three groups of miRNAs can generate pre-miRNA-like hairpins
that serve directly as Dicer substrates without Drosha/DGCR8 process-
ing, such as Mirtrons, endo-shRNAs and murine γ-herpesvirus 68
(MHV68) tRNA-shRNA fusions2. In the Dicer-independent pathway,
pri-miR-451 is processed by Drosha/DGCR8 to generate pre-miR-451
to be incorporated into argonaute 2 (Ago2), the latter cleaves the 30 arm
of pre-miR-451. However, how the mature miR-451 is generated
remains unclear5,6.
2.1. Epigenetic control of microRNA expression
Although much effort has been focused on elucidating the
mechanism of miRNA biogenesis and target gene regulation,relatively little is known and published about the regulation of
miRNA genes themselves. Based on the location in the genome,
miRNA promoters are classiﬁed into three different conditions: 1)
if miRNAs are embedded within introns or exons of host genes,
they can share the same transcriptional control; 2) the embedded
miRNAs also can have their own promoters; 3) if miRNAs
are located in the intergenic regions, they will only be regulated
by their own promoters1,7,8. miR-127 is located in the intron of
retrotransposon-like 1 (Rtl1), an imprinted mouse retrotransposon-
like gene9. It is co-regulated by the Rtl1 promoter, but is also
under the control of its own promoter. The miR-127 gene overlaps
with the miR-433 gene in a compact genomic space10. Their
expression regulation involves epigenetic modiﬁcation via DNA
methylation and histone modiﬁcation11. The miR-127 promoter
represents an example of the complicated miRNAs transcriptional
and epigenetic regulation10,12–15. The nature of miRNA promoter
elements remains one of the most interesting, open problems in the
study of miRNA biogenesis, since their identiﬁcation would aid
the understanding of regulatory networks in which miRNAs play a
crucial role1.
2.2. Transcriptional control of microRNA expression by nuclear
receptors
Nuclear receptors (NRs) are ligand-activated transcription factors that
regulate the expression of target genes by binding to the promoters14–16.
Members of the nuclear receptor superfamily have been proved as
dominant regulators in lipid metabolism. Numerous NRs regulate
miRNAs transcription, including farnesoid X receptor (FXR) and small
heterodimer partner (SHP)1. miR-29a promoter activity was signiﬁ-
cantly increased by FXR through a likely FXR-responsive element17.
FXR plays a key role in homeostasis of cholesterol and bile acids,
indicating the involvement of miR-29a in such processes. A recent
study by Roderburg et al.18 showed that all three members of the
miR-29a family (a, b and c) were signiﬁcantly down-regulated in
mouse liver in both CCl4 and common bile-duct ligation (BDL)
models. miR-199a-3p was also reported to be repressed by FXR19.
SHP is another important nuclear receptor to maintain choles-
terol and bile acid homeostasis by inhibiting the conversion of
cholesterol to bile acids. A microarray proﬁling revealed 21
upregulated miRNAs clustered on chromosome 12, including
miR-433 and miR-127, in Shp / mice10,12,13,20–22. Further study
identiﬁed CREB, which controls hepatic lipid metabolism by
repression of peroxisone proliferator-activated receptor gamma
(PPARγ) and induction of peroxisone proliferator-activated
receptor gamma coactivator (PGC-1), is one of the targets of
miR-43320,23. In addition, miR-433 expression is altered in the
adipose tissue of patients with non-alcoholic fatty liver disease24.
3. miRNA regulation of lipid metabolism
Lipid metabolism was reviewed in great detail elsewhere25.
Dyslipidemia is strongly associated with metabolic syndrome,
miRNAs in lipid metabolism 147obesity, diabetes and fatty liver disease26. Recent studies identiﬁed
miRNAs in the regulation of plasma levels of lipoproteins
and intercellular signaling molecules27,28. Several representative
miRNAs have been shown to have a signiﬁcant impact on lipid
homeostasis29,30.
3.1. miR-122
miR-122 is not only well known as the ﬁrst identiﬁed miRNA to
regulate lipid metabolism, but also the liver-enriched and liver-
speciﬁc miRNA. miR-122-deletion in whole body or speciﬁcally
in the liver showed a marked decrease in total serum cholesterol
and triglyceride (TG) levels. Anti-miR-122 therapy resulted in a
signiﬁcant reduction (25%–30%) of circulating cholesterol
levels27,29,31. A set of cholesterol biosynthesis genes was down-
regulated by an indirect mechanism32, including 3-hydroxy-3-
methylglutaryl-coenzyme A synthase 1 (HMGCS1), 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMGCR) and microsomal
TG transfer protein (MTTP)29. The identiﬁcation of SWI/SNF
related matrix associated actin dependent regulator of chromatin
subfamily d member 1 (Smarcd1/Baf60a) as novel miR-122
targets suggests the direct regulation of these genes33. Interest-
ingly, the miR-122 locus is transcribed in a circadian fashion,
involving the transcriptional repressor nuclear receptor subfamily
1 group D member 1 (NR1D1/REV-ERBα). In liver, most
metabolic pathways are under the circadian control. Both lipid
and cholesterol metabolism are well known for their daytime-
dependent regulation, similar to many other hepatic functions that
require coordination of food intake with nutrient-procession and
energy homeostasis. The molecular mechanism of miR-122 could
represent a novel way of regulation of the circadian rhythm and
hepatic metabolism33.
In addition, miR-122 is involved in several hepatic disorders, as
down-regulation of miR-122 is often associated with hepato-
cellular carcinoma (HCC), and miR-122 is found to bind to two
sites in the 50-UTR of the hepatitis C virus (HCV) genome and
enhance its translation and replication34,35.
3.2. miR-33/33n
miR-33 is another extensively investigated microRNA that mod-
ulates genes involved in lipid metabolism36. The family of miR-33
includes two members, miR-33a and miR-33b. miR-33a and
miR-33b are located in intronic regions within sterol regulatory
element-binding proteins SREBP-2 and SREBP-1, respectively37.
As key transcriptional regulators of lipid metabolism, SREBPs
control many genes involved in cholesterol and fatty acid
biosynthesis and uptake, along with TG and phospholipids
production38. Both miRNAs are co-transcribed with their host
genes and regulate similar physiological processes. Silencing of
miR-33 in vivo increased plasma HDL levels by targeting
adenosine triphosphate-binding cassette transporter A1 (ABCA1)
and adenosine triphosphate-binding cassette transporter G1
(ABCG1), thereby attenuating cholesterol efﬂux to apolipoprotein
A1 (ApoA1) or reducing cholesterol efﬂux to nascent HDL39,40.
Moreover, miR-33-deﬁcient mice had signiﬁcantly higher serum
HDL cholesterol levels41. Interestingly, in addition to other targets
of miR-33, including AMP-activated protein kinase α (AMPKα),
ATPase, aminophospholipid transporter, class I, type 8B, member
1 (ATP8B1), hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit(HADHB), carnitine palmitoyltransferase 1A (CPT1A), sirtuin 6
(SIRT6), glypican 6 (GPC6) and phosphoenolpyruvate carbox-
ykinase 1 (PCK1), the host gene SREBP-1 is one of the targets of
miR-33. This auto-feedback regulation ﬁne-tuned the cholesterol
homeostasis to a delicate balance42.
Intriguingly, as the opposite stand to miR-33, miR-33n shares
similar lipid metabolic network. miR-33n also represses key
regulators involved in cholesterol homeostasis and speciﬁcally
targets cholesterol efﬂux (NPC1), fatty acid metabolism (CROT),
insulin signaling (IRS2) and lipid metabolism (SRC1, SRC3 and
NFYC)43. Although antagonizing miR-33 may develop as an
attractive strategy for raising plasma HDL and are against
atherosclerosis, caution should be taken because long-term ther-
apeutic silencing of miR-33 may increase circulating triglyceride
levels44–46.
3.3. miR-27a/27b
Retinoid X receptor alpha (RXRα) plays a central role in
adipogenesis through forming a heterodimer with PPARγ and
other nuclear receptors. Both miR-27a and miR-27b are demon-
strated to target RXRα and regulate fat metabolism47. Further-
more, PPARγ is a target of miR-27b48 and ABCA1 a target of
miR-27a. Due to their sharing of the same seed region between
miR-27a and miR-27b, it is reasonable to predict that both
miRNAs could target PPARγ and ABCA1. Overexpression of
miR-27a accelerates adipolysis by releasing more glycerol and free
fatty acids in the adipocytes49 and represses lipid storage in cells.
In addition, miR-27a inhibits the expression of many lipid
metabolic genes, including fatty acid synthase (FASN), SREBP-1,
SREBP-2, PPARα and PPARγ, as well as ApoA1, ApoB100 and
ApoE350. Thus, miR-27 may regulate lipid metabolism by redu-
cing lipid synthesis and increasing lipid secretion from cells.
3.4. miR-378/378n
miR-378 and miR-378n are embedded in the PGC-1β gene and
counterbalance the metabolic actions of PGC-1β. A reduction of
adipocyte size in miR-378/378n knockout mice indicates that both
miRNAs are required for efﬁcient hypertrophy and lipid uptake in
white adipocytes. Several targets of miR-378/378n are found,
including carnitine O-acetyltransferase (CRAT), mediator complex
subunit 13 (MED13)51, estrogen-related receptor gamma (ERRγ),
GA binding protein transcription factor alpha subunit (GABPA)52,
insulin-like growth factor 1 receptor (IGF1R)53, and ABCG154.
miR-378 is also downregulated in 4-hydroxynonenal (HNE), one
of several lipid oxidation products, treated cells55. In addition,
C/EBPα and C/EBPβ positively increase miR-378/378n transcrip-
tional activity56,57. Furthermore, inhibition of miR-378 attenuates
lipolysis and reduces the expression of lipase hormone-sensitive
(LIPE), perilipin 1 (PLIN1) and patatin-like phospholipase domain
containing 2 (PNPLA2), a set of genes encoding key lipolytic
regulators58.
3.5. miR-34a
miR-34a has multiple roles in the regulation of cell cycle,
apoptosis, differentiation and migration because of its expressional
control by p5359,60. However, its induction by FXR raised the
possibility of a new role of miR-34a in lipid metabolism61.
Sirtuin1 (SIRT1) was identiﬁed as one of the targets of miR-34a.
Figure 1 Regulatory role of miRNAs in lipid metabolism. Light green boxes highlight miRNAs involved in lipid metabolism. Blue boxes
represent target genes of miRNAs. The miRNAs and their respective targets are linked by arrows.
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PGC-1α62. On the other hand, miR-34a negatively regulates
RXRα through binding to its 30-UTR and decrease the induction
of cytochrome P450 family 26 (CYP26) and cytochrome P450
family 3 subfamily A polypeptide 4 (CYP3A4)63. Moreover,
through targeting ﬁbroblast growth factor receptor 1 (FGFR1),
miR-34a contributes to attenuating ﬁbroblast growth factor 21
(FGF21) signaling in obese mice. The expression of miR-34a was
elevated in obesity, indicating its potential role in inhibiting fat
browning and weight loss64.
3.6. miR-21
The expression of miR-21 was decreased in liver from high-fat
diet-fed mice compared to chow fed mice. Overexpression of
miR-21 markedly blocked stearic acid (SA) induced intracellular
lipid accumulation by targeting fatty acid-binding protein 7
(FABP7)65. In miR-21 knockout mice, a group of lipid metabolic
genes was changed compared with wild-type mice. PPARα and
insulin-like growth factor binding protein 3 (IGFBP3) were also
targeted directly by miR-2166–68. Further studies showed that miR-
21 targeted programmed cell death 4 (PDCD4) to regulate lipid
accumulation through the toll-like receptor 4 (TLR4) and NF-ĸB
pathway in lipopolysaccharide (LPS)-stimulated macrophages68.
Additional miRNAs were also shown to regulate lipid metabo-
lism. miR-758, miR-26, and miR-106b all targeted ABCA1.
miR-370 targeted CPT1A and miR-24 targeted insulin induced
gene 1 (INSIG1). Altogether these ﬁndings suggest that miRNAs
play important roles in regulating lipid and lipoprotein home-
ostasis, which is summarized in Fig. 1.4. Therapeutic potential of microRNAs
Although miRNAs represent a new class of potential targets for
therapeutic intervention, there are obstacles to their clinical
application, such as poor efﬁciency for cellular uptake. Lipofection
of an antisense oligonucleotide based on a locked nucleic acids(LNA)/20-O-methylene mixmer or electroporation of a peptide
nucleic acid (PNA) oligomer is effective at blocking miR-122
activity, highlighting the use of miRNA in future therapeutic
application69. A non-covalent peptide-based strategy was used for
efﬁcient delivery of miR-122 mimic or inhibitor, which appeared
to be effective to alter cholesterol levels without cytotoxicity70.
The recently emerged lipid-based nanoparticles (LNPs) and LNP-
DP1 provide more alternate ways for delivering siRNA and
miRNA in vitro and in vivo71.5. Conclusion and perspectives
A key role of miRNAs in lipoprotein and lipid metabolism is
emerging. Because multiple genes can be targeted by one miRNA
and one gene may be targeted by a group of miRNAs, the mRNA
and miRNA regulatory network remains complicated. Recent
evidence suggests that circulating extracellular miRNAs can also
be biologically active in intercellular communication72. Future
research works that integrate proteomics, systems biology and
high-through technologies will help to develop better therapeutic
strategies that target miRNAs.Acknowledgments
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